TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Child behavior checklist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: System Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative incidence of hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of adaptive immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate of FDG-PET/CT normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Grade 3-5 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) on Vorinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 24-month progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Rates of change of clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of change of imaging outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of change of biomic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28 Day All-cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Maximum observed concentration from Time Zero to End of Dosing Interval (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative neonatal survival
Endpoint domain: Mortality/survival
Primary endpoint: Long term neonatal survival
Endpoint domain: Mortality/survival
Primary endpoint: Minimum Effective Dose (MED)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of brentuximab vedotin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative 48-hour postoperative morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in right/left ventricular synchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in functional capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oculomotor Processes score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visuo-perceptual process composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual-attentional process score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-T
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Remission With Incomplete Blood Count Recovery (CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of All-Cause Mortality and Adjudicated Cytomegalovirus End Organ Disease
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with adverse events (AEs) in Part A
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse events (AEs) in Part B
Endpoint domain: Adverse events/effects
Primary endpoint: Vital sign assessment in Part A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital sign assessment in Part B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of prostate lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cognitive and behavioural assessment in ALS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Alcohol Urge
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Alcohol Drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Opioid Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of graft versus host disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Best skin quality by blinded live evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Birth defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes from baseline Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline Clinical Global Impression (CGI) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes from baseline Simpson-Angus Rating Scale (SAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline Abnormal involuntary movement scale (AIMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of unanticipated adverse device effects (UADE)
Endpoint domain: Adverse events/effects
Primary endpoint: GH increase after Arginine Provocation Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Arm impairment assessed by Fugl-Meyer Assessment-upper limb (FMA-UL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Language function assessed by Western Aphasia Bedside (WAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive impairment assessed by Montreal Cognitive Assessment (MoCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anxiety and Depression assessed by Hospital Anxiety Depression scale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Apathy assessed by Apathy Evaluation Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Extended high frequency audiometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Laboratory Abnormalities Reported as TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery of Static 2-point Discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of vaccine responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lactate production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence and severity of coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Tumor Lesions Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of MRI Alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of MR Alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of rTMS Sessions Completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Significant hematuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urinary outcomes
Primary endpoint: Biochemical Progression-free survival (bPFS)
Endpoint domain: Mortality/survival
Primary endpoint: National Institutes of Health Stroke Severity (NIHSS) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Neurological status of the subject
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Percentage of participants who change to once weekly NeoRocormon
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants with local intolerabilities (pain/allergic reactions)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who withdrew due to inability to use RecoPen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants who changed dose during treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lesion Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of pediatric neoplastic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in corticospinal reserve capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Center of force evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate on Induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in global IBS symptom relief score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of early deaths
Endpoint domain: Mortality/survival
Primary endpoint: mother own milk feeding rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic Rupture
Endpoint domain: Mortality/survival
Primary endpoint: Major Device-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Minimum True Lumen Diameter Adjacent to Treated Segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinically Significant Cardiac Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Nosocomial Infections (UTI, Sepsis, and Pneumonia)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Neurologic Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain relief assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of PAC19QoL Measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 13
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Romantic Relationship Quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Adherent Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Local Disease Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: short-term prognosis
Endpoint domain: Mortality/survival
Primary endpoint: Acute Gastrointestinal Toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Social, environmental and economic difficulties encountered by parents
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change From Baseline in ADHD Symptoms Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report willingness to consider quitting smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Middle Cerebral Artery Blood Velocity (MCAv)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time Trial Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and compliance
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute change in plasma ALP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial Bias Compound Score (SBCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty and pre-frailty diagnosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Transcutaneous carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Drinker Inventory of Consequences (DrInC) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: adolescent HIV/STD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Results of neuropsychological intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: acute behavioral pain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Object response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inner harmony
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in fidelity of school implementation of PBIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change over time in student disciplinary outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in student academic outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of measurements within 5 mmHg of standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) / Recommended Phase 2 Dose (RPTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the structure of the left atrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in the function of the left atrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced total time spent sitting at work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced number of prolonged sitting periods (>30 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased number of breaks from sitting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family Caregiver Well-Being using GAD-7 Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Family Caregiver Well-Being using PHQ-8 Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Family Caregiver Well-Being Using Zarit Burden Interview
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Neuro Patients Well-Being Using GAD-7 Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neuro Patients Well-Being using PHQ-8 Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of malignant and pre-malignant changes in polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients with Potentially inappropriate medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first new malaria infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of molecularly confirmed new malaria infections
Endpoint domain: Adverse events/effects
Primary endpoint: Momentary psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Momentary eudaimonic well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Momentary hedonic well-being (state positive and negative affect)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients with occult HBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total Symptom Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tidal volume distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forearm Blood Flow (FBF) Response to Acetylcholine (ACh)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Forearm Blood Flow (FBF) Response to Sodium Nitroprusside (NTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endothelial Tissue Type Plasminogen Activator (t-PA) Release in Response to Bradykinin (BDK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in homeostatic model assessment of insulin resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in methylation of gene markers for Barrett's esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Difference in methylation of gene markers for esophageal carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Difference in methylation of gene markers for gastric cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time from Randomization to Clinical Diagnosis of Atrial Fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Days Covered (PDC) by Direct Oral Anti-Coagulant (DOAC) Prescription Fills
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Medical Outcomes Study (MOS)-36 Physical functioning scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in visual analog scale (VAS) of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Timed performance of functional tasks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of Participants with Major Pathologic Response (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of participants with 3-5 grade Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants without delays of surgery due to treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inattentive Symptoms Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 7-day Point Prevalence Smoking Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak CK-MB/ Troponin-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in brain amyloid deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subjective pain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stance Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute time to hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in Bone Marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Active Substance Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Single Leg Hop Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of ADAS-cog 11 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sniff Nasal Inspiratory Pressure (SNIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of spontaneous pain on the operated hemithorax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of spontaneous pain on the operated hemithorax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of pressure pain threshold on the operated hemithorax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of target recruitment reached
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinically Global Impression-Improvement scale (CGI-I; Change from baseline)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Liebowitz Social Anxiety Scale, Self-report version (LSAS-SR; Change from baseline)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success rate of outpatient laparoscopic sacrocolpopexy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful cervical ripening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Renal tissue stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Magnetization transfer ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion quantified as blood flow in mL/s
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in questionnaire response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Children's days off school
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of use of high-risk drugs in perioperative setting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time needed to perform EE measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes